PMID- 22914611
OWN - NLM
STAT- MEDLINE
DCOM- 20130926
LR  - 20161020
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 21
IP  - 3
DP  - 2013 May
TI  - Correlation between HER2 determined by fluorescence in situ hybridization and 
      reverse transcription-polymerase chain reaction of the oncotype DX test.
PG  - 196-9
LID - 10.1097/PAI.0b013e3182632ff5 [doi]
AB  - The human epidermal growth factor receptor 2 (HER2) gene is amplified and its 
      protein product overexpressed in about 20% of invasive breast cancers. Despite 
      more than a decade of efforts to standardize HER2 testing, controversy persists 
      regarding the most optimal testing method. Recently, Oncotype DX reports have 
      begun including HER2 results in addition to the previously reported Recurrence 
      Score. We compared HER2 results obtained by fluorescence in situ hybridization 
      (FISH) in our laboratories with HER2 results obtained by reverse 
      transcription-polymerase chain reaction (RT-PCR) as documented in the Oncotype DX 
      report. We then sought to identify potentially significant characteristics in the 
      discrepant cases. We identified breast cancer patients with estrogen 
      receptor-positive, lymph node-negative tumors who had Oncotype DX testing 
      performed between September 2008 and March 2012. Patient and tumor 
      characteristics including HER2 FISH and Oncotype DX test results were recorded. 
      Image analysis was performed on cases with discrepancy between the HER2 FISH and 
      Oncotype DX HER2 results to determine the relative proportion of invasive tumor. 
      Eight of 194 (4.1%) cases showed discrepancy between HER2 FISH and Oncotype DX 
      RT-PCR results. Although the overall percent agreement (96%) and percent negative 
      agreement (100%) were high, percent positive agreement was only 50%. Three of 8 
      (38%) discrepant cases showed heterogeneous amplification by FISH. Seven of 8 
      (88%) discrepant cases had <50% invasive tumor in the Oncotype DX tissue block. 
      Percent positive agreement between HER2 FISH and Oncotype DX RT-PCR is low. 
      Multiple factors may contribute to this discrepancy including a suboptimal 
      microdissection and possibly heterogeneous amplification of HER2 gene in some 
      cases.
FAU - Dvorak, Leah
AU  - Dvorak L
AD  - University of Minnesota, Fairview, MN, USA.
FAU - Dolan, Michelle
AU  - Dolan M
FAU - Fink, James
AU  - Fink J
FAU - Varghese, Linda
AU  - Varghese L
FAU - Henriksen, Jonathan
AU  - Henriksen J
FAU - Gulbahce, H Evin
AU  - Gulbahce HE
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*genetics
MH  - Breast Neoplasms/diagnosis/*genetics/*pathology
MH  - Carcinoma/diagnosis/*genetics/*pathology
MH  - Female
MH  - Genotyping Techniques
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/standards
MH  - Lymph Nodes/pathology
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Receptor, ErbB-2/*genetics
MH  - Receptors, Estrogen/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction/standards
EDAT- 2012/08/24 06:00
MHDA- 2013/09/27 06:00
CRDT- 2012/08/24 06:00
PHST- 2012/08/24 06:00 [entrez]
PHST- 2012/08/24 06:00 [pubmed]
PHST- 2013/09/27 06:00 [medline]
AID - 10.1097/PAI.0b013e3182632ff5 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2013 May;21(3):196-9. doi: 
      10.1097/PAI.0b013e3182632ff5.